Japan filing for fibrillation set to sustain MTP's bisoprolol sales
This article was originally published in Scrip
Executive Summary
Mitsubishi Tanabe Pharma (MTP) is looking to expand the uses of its selective beta1-antagonist Maintate (bisoprolol fumarate) in Japan through an approval filing for the additional indication of chronic atrial fibrillation.